Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,970 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N, Ishizawa K, Yamamoto J, Watanabe T, Uike N, Choi I, Terui Y, Usuki K, Nagai H, Uoshima N, Tobinai K; Japanese Bendamustine Lymphoma Study Group. Ohmachi K, et al. Among authors: itoh k. Cancer Sci. 2010 Sep;101(9):2059-64. doi: 10.1111/j.1349-7006.2010.01635.x. Cancer Sci. 2010. PMID: 20626754 Free PMC article. Clinical Trial.
Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma.
Ogawa Y, Tobinai K, Ogura M, Ando K, Tsuchiya T, Kobayashi Y, Watanabe T, Maruyama D, Morishima Y, Kagami Y, Taji H, Minami H, Itoh K, Nakata M, Hotta T. Ogawa Y, et al. Among authors: itoh k. Cancer Sci. 2008 Jan;99(1):140-4. doi: 10.1111/j.1349-7006.2007.00638.x. Epub 2007 Oct 27. Cancer Sci. 2008. PMID: 17970782 Free PMC article. Clinical Trial.
Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma.
Tobinai K, Watanabe T, Ogura M, Morishima Y, Hotta T, Ishizawa K, Itoh K, Okamoto S, Taniwaki M, Tsukamoto N, Okumura H, Terauchi T, Nawano S, Matsusako M, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Hayashi M, Endo K. Tobinai K, et al. Among authors: itoh k. Cancer Sci. 2009 Jan;100(1):158-64. doi: 10.1111/j.1349-7006.2008.00999.x. Epub 2008 Oct 24. Cancer Sci. 2009. PMID: 19018755 Free article. Clinical Trial.
Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab.
Tobinai K, Watanabe T, Tanimoto K, Maruyama D, Nakata M, Itoh K, Morishima Y, Ogura M, Usui N, Kasai M, Terauchi T, Nawano S, Matsusako M, Matsuno Y, Nakamura S, Mori S, Ohashi Y. Tobinai K, et al. Among authors: itoh k. Cancer Sci. 2009 Jul;100(7):1344-50. doi: 10.1111/j.1349-7006.2009.01162.x. Epub 2009 Apr 21. Cancer Sci. 2009. PMID: 19432900 Free article. Clinical Trial.
Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma.
Tobinai K, Ishizawa K, Ogura M, Itoh K, Morishima Y, Ando K, Taniwaki M, Watanabe T, Yamamoto J, Uchida T, Nakata M, Terauchi T, Nawano S, Matsusako M, Hayashi M, Hotta T. Tobinai K, et al. Among authors: itoh k. Cancer Sci. 2009 Oct;100(10):1951-6. doi: 10.1111/j.1349-7006.2009.01247.x. Epub 2009 Jun 17. Cancer Sci. 2009. PMID: 19594547 Free PMC article. Clinical Trial.
Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results.
Tobinai K, Ogura M, Itoh K, Kinoshita T, Hotta T, Watanabe T, Morishima Y, Igarashi T, Terauchi T, Ohashi Y; All Collaborators of the IDEC-C2B8 Study Group in Japan. Tobinai K, et al. Among authors: itoh k. Cancer Sci. 2010 Dec;101(12):2579-85. doi: 10.1111/j.1349-7006.2010.01703.x. Cancer Sci. 2010. PMID: 20942866 Free PMC article. Clinical Trial.
Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma.
Tobinai K, Ogura M, Maruyama D, Uchida T, Uike N, Choi I, Ishizawa K, Itoh K, Ando K, Taniwaki M, Shimada N, Kobayashi K. Tobinai K, et al. Among authors: itoh k. Int J Hematol. 2010 Nov;92(4):563-70. doi: 10.1007/s12185-010-0707-5. Epub 2010 Oct 23. Int J Hematol. 2010. PMID: 20972652 Clinical Trial.
Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
Tobinai K, Igarashi T, Itoh K, Kurosawa M, Nagai H, Hiraoka A, Kinoshita T, Uike N, Ogura M, Nawano S, Mori S, Ohashi Y; IDEC-C2B8 Study Group. Tobinai K, et al. Among authors: itoh k. Cancer Sci. 2011 Sep;102(9):1698-705. doi: 10.1111/j.1349-7006.2011.02001.x. Epub 2011 Jul 8. Cancer Sci. 2011. PMID: 21645173 Free article. Clinical Trial.
Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden.
Igarashi T, Ogura M, Itoh K, Taniwaki M, Ando K, Kuroda Y, Yamamoto K, Uike N, Tomita A, Nagai H, Kurosawa M, Mori S, Nawano S, Terauchi T, Ohashi Y, Tobinai K. Igarashi T, et al. Among authors: itoh k. Int J Hematol. 2016 Dec;104(6):700-708. doi: 10.1007/s12185-016-2097-9. Epub 2016 Oct 6. Int J Hematol. 2016. PMID: 27714587 Clinical Trial.
3,970 results